Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
D
Douglas B. Johnson
A
Amin H. Nassar
A
Ayesha Aijaz
A
Andrew Knight
M
Mehmet Murat Zerey
B
Brian I. Rini
A
Abdul Rafeh Naqash
R
Ryan J. Sullivan
(Massachusetts General Hospital Cancer Center Boston Massachusetts USA)
Article Details
Journal
Nature Reviews Clinical Oncology
Volume / Issue
Vol. 23, Issue 5
Published
May 01, 2026
Pages
341-355
ISSN
1759-4774
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Clinical Oncology
Springer Science and Business Media LLC
ISSN: 1759-4774 Q1 Medicine
Authors (8)
D
Douglas B. Johnson
A
Amin H. Nassar
A
Ayesha Aijaz
A
Andrew Knight
M
Mehmet Murat Zerey
B
Brian I. Rini
A
Abdul Rafeh Naqash
R
Ryan J. Sullivan
Massachusetts General Hospital Cancer Center Boston Massachusetts USA
Related Articles from this Journal
Ibrutinib improves overall survival in patients with mantle cell lymphoma
Peter Sidaway
Jul 2026
10.1038/s41571-026-01166-7
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA
Diana Romero
Jul 2026
10.1038/s41571-026-01169-4
Clinical implementation of multi-cancer early detection tests: can we find a path forward?
Ariadna Tibau, Aaron S. Kesselheim
Jul 2026
10.1038/s41571-026-01158-7
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer
David Killock
Jul 2026
10.1038/s41571-026-01162-x
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer
W. K. Jacky Lam, Brigette B. Y. Ma
Jul 2026
10.1038/s41571-026-01157-8